Keith Ward
Directeur/Bestuurslid bij SKYE BIOSCIENCE, INC.
Vermogen: - $ op 30-04-2024
Profiel
Keith W.
Ward is the President & Chief Executive Officer of InterveXion Therapeutics LLC since 2019 and an Independent Director at Skye Bioscience, Inc. since 2021.
He founded Kuria Therapeutics, Inc. in 2022 and holds the title of President & Chief Executive Officer.
Dr. Ward was the Global VP-Pharmaceutical Research & Development at Bausch & Lomb, Inc. from 2008 to 2011, the Chief Development Officer & Executive VP at Reata Pharmaceuticals, Inc. from 2011 to 2019, and the Chief Development Advisor at Unicycive Therapeutics, Inc. from 2020 to 2022.
He was also the Director-Preclinical Drug Discovery at GlaxoSmithKline LLC.
Dr. Ward holds a doctorate from The University of North Carolina at Chapel Hill and an undergraduate degree from Northeast Louisiana University.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
SKYE BIOSCIENCE, INC.
-.--% | 29-02-2024 | 0 ( -.--% ) | - $ | 30-04-2024 |
Actieve functies van Keith Ward
| Bedrijven | Functie | Begin |
|---|---|---|
| SKYE BIOSCIENCE, INC. | Directeur/Bestuurslid | 14-12-2021 |
InterveXion Therapeutics LLC
 InterveXion Therapeutics LLC Pharmaceuticals: MajorHealth Technology InterveXion Therapeutics LLC develops drugs and antibody-based therapies. The firm develops monoclonal antibodies to treat substance abuse from PCP and methamphetamine. The company was founded by S. Michael Owens, W. Brooks Gentry, Ralph Henry, Misty Stevens and Gerald A. Damerow in 2004 and is headquartered in Little Rock, AR. | Algemeen Directeur | 01-01-2019 |
Kuria Therapeutics, Inc.
 Kuria Therapeutics, Inc. BiotechnologyHealth Technology Kuria Therapeutics, Inc. is a company that focuses on the biology of NRF2, which is the body's master regulator of the cytoprotective, antioxidant, and detoxification response. The company is based in Little Rock, AZ. The company is developing a potent NRF2 activator for multiple ophthalmic and dermatologic conditions. The company was founded by Keith W. Ward, Misty Stevens. Keith W. Ward has been the CEO since incorporation. | Algemeen Directeur | 01-02-2022 |
Eerdere bekende functies van Keith Ward
| Bedrijven | Functie | Einde |
|---|---|---|
| UNICYCIVE THERAPEUTICS, INC. | Corporate Officer/Principal | 01-07-2022 |
| REATA PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01-03-2019 |
Bausch & Lomb, Inc.
 Bausch & Lomb, Inc. Medical SpecialtiesHealth Technology Bausch & Lomb, Inc. develops, manufactures, and markets eye health products. It offers over-the-counter supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care, ophthalmic surgical devices, and instruments. The company was founded by John Jacob Bausch and Henry Lomb in 1853 and is headquartered in Rochester, NY. | Corporate Officer/Principal | 01-06-2011 |
GlaxoSmithKline LLC
 GlaxoSmithKline LLC Pharmaceuticals: MajorHealth Technology GlaxoSmithKline LLC engages in discovering, developing, and delivering medicines, vaccines, and other healthcare products. It offers prescription medicines that treat various diseases, including cancer, HIV/AIDS, depression, diabetes, high blood pressure, herpes, asthma, migraine, and heart diseases, as well as stomach and skin problems, infections, and flu. It also provides vaccines for children and adults; and over-the-counter products. The company was founded in 1929 and is headquartered in Philadelphia, PA. | Corporate Officer/Principal | - |
Opleiding van Keith Ward
| Northeast Louisiana University | Undergraduate Degree |
| The University of North Carolina at Chapel Hill | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| UNICYCIVE THERAPEUTICS, INC. | Health Technology |
| SKYE BIOSCIENCE, INC. | Health Technology |
| Bedrijven in privébezit | 5 |
|---|---|
Reata Pharmaceuticals, Inc.
 Reata Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Reata Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. Its product candidates are bardoxolone methyl and omaveloxolone, which activate the transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation. The company was founded by J. Warren Huff in 2002 and is headquartered in Plano, TX. | Health Technology |
Bausch & Lomb, Inc.
Bausch & Lomb, Inc. Medical SpecialtiesHealth Technology Bausch & Lomb, Inc. develops, manufactures, and markets eye health products. It offers over-the-counter supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care, ophthalmic surgical devices, and instruments. The company was founded by John Jacob Bausch and Henry Lomb in 1853 and is headquartered in Rochester, NY. | Health Technology |
GlaxoSmithKline LLC
GlaxoSmithKline LLC Pharmaceuticals: MajorHealth Technology GlaxoSmithKline LLC engages in discovering, developing, and delivering medicines, vaccines, and other healthcare products. It offers prescription medicines that treat various diseases, including cancer, HIV/AIDS, depression, diabetes, high blood pressure, herpes, asthma, migraine, and heart diseases, as well as stomach and skin problems, infections, and flu. It also provides vaccines for children and adults; and over-the-counter products. The company was founded in 1929 and is headquartered in Philadelphia, PA. | Health Technology |
InterveXion Therapeutics LLC
InterveXion Therapeutics LLC Pharmaceuticals: MajorHealth Technology InterveXion Therapeutics LLC develops drugs and antibody-based therapies. The firm develops monoclonal antibodies to treat substance abuse from PCP and methamphetamine. The company was founded by S. Michael Owens, W. Brooks Gentry, Ralph Henry, Misty Stevens and Gerald A. Damerow in 2004 and is headquartered in Little Rock, AR. | Health Technology |
Kuria Therapeutics, Inc.
Kuria Therapeutics, Inc. BiotechnologyHealth Technology Kuria Therapeutics, Inc. is a company that focuses on the biology of NRF2, which is the body's master regulator of the cytoprotective, antioxidant, and detoxification response. The company is based in Little Rock, AZ. The company is developing a potent NRF2 activator for multiple ophthalmic and dermatologic conditions. The company was founded by Keith W. Ward, Misty Stevens. Keith W. Ward has been the CEO since incorporation. | Health Technology |